共识制定委员会：中国心力衰竭中心联盟专家委员会
共识制定工作组
组长：杨杰孚、李为民、廖玉华
主要执笔人：廖玉华、余淼、袁璟、廖梦阳
中国心力衰竭中心联盟专家委员会：
杨杰孚、李为民、廖玉华、董吁钢、李新立、周京敏、项美香、郭延松、傅向华、李广平、严激、王华、苑海涛、艾力曼·马合木提、金玮、张庆、孙志军、王江、孔洪、黎励文、张瑶、董蔚、白玲、徐东杰、袁璟、刘晨、任景怡、杨萍、陈牧雷、毛威、徐验、孙健、李萍、杨丽霞、华伟、井海云
Consensus of Chinese experts on the clinical application of SGLT2 inhibitors in heart failure
-
摘要: 钠-葡萄糖协同转运蛋白-2(SGLT2)抑制剂已经被推荐为治疗心力衰竭的新四联药物之一。本专家共识重点介绍SGLT2抑制剂治疗心力衰竭的作用机制、药物代谢动力学特征、循证医学证据以及临床实践经验，为中国心力衰竭患者提供临床应用的规范与建议。
-
关键词:
- 心力衰竭 /
- 钠-葡萄糖协同转运蛋白-2抑制剂 /
- 血流动力学 /
- 心脏代谢重构
Abstract: Sodium glucose cotransporter-2(SGLT2) inhibitors have been recommended as one of the four foundational therapies for heart failure. This expert consensus focuses on the mechanism, pharmacokinetic characteristics, evidence-based medicine, and clinical experience of SGLT2 inhibitors in the treatment of heart failure, and provides clinical standards and suggestions for patients with heart failure in China. -
-
图 1 SGLT2抑制剂治疗心衰的临床应用路径
Figure 1. Clinical application of SGLT2 inhibitors in the treatment of heart failure
表 1 常见SGLT2抑制剂药物代谢动力学参数
Table 1. Pharmacokinetic parameters of common SGLT2 inhibitors
药物代谢动力学参数 达格列净 恩格列净 卡格列净 艾托格列净 索格列净 绝对口服生物利用度(OBA)/% 78 78 65 100 N/A 达峰时间(Tmax)/h 2 1~2 1~2 0.5~1.5 2 血浆分布体积(Vd)/L 118 73.8 83.5 86 N/A 血浆蛋白结合率(PPB)/% 98 86 99 93 N/A 药物代谢酶 UGT1A9 UGT1A3/UGT1A8/UGT1A9/UGT2B7 UGT1A9/UGT2B4/CYP3A4 UGT1A9/UGT2B7/CYP3A4 UGT1A1/UGT1A9/UGT2B7/UGT3A4 消除半衰期(T1/2)/h 12.9 12.4 10~13 11~17 13.5~20.7 清除部位 肠道、胆汁、肾脏 N/A N/A N/A N/A 尿排泄率/% 75 54 33 51 N/A 粪排泄率/% 21 41 60 41 N/A 抑制浓度(IC50)/nM 1.2 3.1 2.7 0.9 N/A SGLT2/SGLT1(IC50)* 1∶1400 3∶8300 3∶700 N/A 2∶40 心衰研究主要终点
HR (95% CI)DAPA-HF
0.74(0.65, 0.85)EMPEROR-Reduced
0.75(0.65, 0.86)- - SOLOIST-WHF
0.67(0.52, 0.85)*药物对不同SGLT受体的选择性。IC50代表半抑制浓度。 
下载: 导出CSV
表 2 SGLT2抑制剂治疗心衰临床应用的建议
Table 2. Recommendations for the clinical application of SGLT2 inhibitors in the treatment of heart failure
共识 建议 推荐级别 证据水平 2022年《心力衰竭SGLT2抑制剂临床应用的中国专家共识》 2型糖尿病无论是已有心血管疾病还是心血管风险高危的患者，都应该使用SGLT2抑制剂预防心衰住院 Ⅰ A 对于有症状的慢性HFrEF患者，无论是否有2型糖尿病，建议使用SGLT2抑制剂来减少心衰住院率和心血管死亡率 Ⅰ A 对于无糖尿病，体重指数(BMI)>22 kg/m2的中国心衰患者，建议使用SGLT2抑制剂治疗心衰，增加临床获益 Ⅰ C* 对于AHF或心衰恶化患者，待病情稳定后，建议尽早使用SGLT2抑制剂治疗心衰，增加临床获益 Ⅱa B 对于有症状的慢性HFpEF患者，SGLT2抑制剂有助于降低心衰住院率和心血管死亡率 Ⅱa B *本文列举所有的SGLT2抑制剂治疗心衰CVOT临床试验，纳入2型糖尿病或非糖尿病患者的BMI基本上为28(24~32) kg/m2，中国人BMI最佳值为20~22 kg/m2，由于SGLT2抑制剂具有减重作用，专家建议中国非糖尿病BMI>22 kg/m2的心衰患者推荐应用SGLT2抑制剂。
推荐级别：Ⅰ级指已证实和(或)一致公认有益、有用和有效的操作或治疗，推荐使用；Ⅱ级指有用和(或)有效的证据尚有矛盾或存在不同观点的操作或治疗；Ⅱa级指有关证据/观点倾向于有用和(或)有效，应用这些操作或治疗是合理的，应当考虑使用；Ⅱb级指有关证据/观点尚不能被充分证明有用和(或)有效，可以考虑使用；Ⅲ级指已证实和(或)一致公认无用和(或)无效，并对一些病例可能有害的操作或治疗，不推荐使用。证据水平：A级资料来源于多项随机对照研究或荟萃分析；B级资料来源于单项随机对照研究或大型非随机对照研究；C级资料来源于专家共识和(或)小型研究、回顾性分析、注册研究。
下载: 导出CSV
-
[1] Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure[J]. J Card Fail, 2021.
[2] Wang H, Chai K, Du M, et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis[J]. Circ Heart Fail, 2021, 14(10): e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406
[3] Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD): a multicentre, randomised, open-label trial[J]. Lancet, 2009, 373(9681): 2125-2135. doi: 10.1016/S0140-6736(09)60953-3
[4] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128. doi: 10.1056/NEJMoa1504720
[5] Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes[J]. N Engl J Med, 2017, 377(7): 644-657. doi: 10.1056/NEJMoa1611925
[6] Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2019, 380(4): 347-357. doi: 10.1056/NEJMoa1812389
[7] 廖梦阳, 廖玉华, 余淼, 等. SGLT2抑制剂治疗心力衰竭潜在机制的新认识[J]. 临床心血管病杂志, 2022, 38(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202201001.htm
[8] Tang J, Ye L, Yan Q, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism[J]. Front Pharmacol, 2022, 13: 800490. doi: 10.3389/fphar.2022.800490
[9] Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 369-384. doi: 10.1016/S2213-8587(13)70208-0
[10] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes[J]. N Engl J Med, 2016, 375(4): 323-334. doi: 10.1056/NEJMoa1515920
[11] Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study[J]. Cardiovasc Diabetol, 2017, 16(1): 138. doi: 10.1186/s12933-017-0621-8
[12] Li H, Shin SE, Seo MS, et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels[J]. Life Sci, 2018, 197: 46-55. doi: 10.1016/j.lfs.2018.01.032
[13] Maruyama T, Takashima H, Oguma H, et al. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease[J]. Diabetes Technol Ther, 2019, 21(12): 713-720. doi: 10.1089/dia.2019.0212
[14] Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis[J]. J Clin Endocrinol Metab, 2020, 105(4).
[15] Mazer CD, Hare G, Connelly PW, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[J]. Circulation, 2020, 141(8): 704-707. doi: 10.1161/CIRCULATIONAHA.119.044235
[16] Yurista SR, Silljé H, Oberdorf-Maass SU, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction[J]. Eur J Heart Fail, 2019, 21(7): 862-873. doi: 10.1002/ejhf.1473
[17] Kolesnik E, Scherr D, Rohrer U, et al. SGLT2 Inhibitors and Their Antiarrhythmic Properties[J]. Int J Mol Sci, 2022, 23(3): 1678. doi: 10.3390/ijms23031678
[18] Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF[J]. Eur Heart J, 2021, 42(36): 3727-3738. doi: 10.1093/eurheartj/ehab560
[19] Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials[J]. Heart Rhythm, 2021, 18(7): 1098-1105. doi: 10.1016/j.hrthm.2021.03.028
[20] Zhou L, Cryan EV, D'Andrea MR, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1(SGLT1)[J]. J Cell Biochem, 2003, 90(2): 339-346. doi: 10.1002/jcb.10631
[21] Di Franco A, Cantini G, Tani A, et al. Sodium-dependent glucose transporters(SGLT)in human ischemic heart: A new potential pharmacological target[J]. Int J Cardiol, 2017, 243: 86-90. doi: 10.1016/j.ijcard.2017.05.032
[22] Banerjee SK, McGaffin KR, Pastor-Soler NM, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states[J]. Cardiovasc Res, 2009, 84(1): 111-118. doi: 10.1093/cvr/cvp190
[23] 中国心衰中心联盟. 舒张性心力衰竭早期防治专家建议[J]. 临床心血管病杂志, 2021, 37(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202101001.htm
[24] Díaz-Rodríguez E, Agra RM, Fernández ÁL, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability[J]. Cardiovasc Res, 2018, 114(2): 336-346. doi: 10.1093/cvr/cvx186
[25] Zhang N, Feng B, Ma X, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2019, 18(1): 107. doi: 10.1186/s12933-019-0914-1
[26] Herat LY, Magno AL, Rudnicka C, et al. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection[J]. JACC Basic Transl Sci, 2020, 5(2): 169-179. doi: 10.1016/j.jacbts.2019.11.007
[27] Kaur P, Behera BS, Singh S, et al. "The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics"[J]. Eur J Pharmacol, 2021, 904: 174169. doi: 10.1016/j.ejphar.2021.174169
[28] Wright EM. SGLT2 Inhibitors: Physiology and Pharmacology[J]. Kidney360, 2021, 2(12): 2027-2037. doi: 10.34067/KID.0002772021
[29] McMurray J, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303
[30] Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J]. N Engl J Med, 2020, 383(15): 1413-1424. doi: 10.1056/NEJMoa2022190
[31] Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J]. Lancet, 2020, 396(10254): 819-829. doi: 10.1016/S0140-6736(20)31824-9
[32] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461. doi: 10.1056/NEJMoa2107038
[33] Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction[J]. Eur Heart J, 2022, 43(5): 416-426. doi: 10.1093/eurheartj/ehab798
[34] Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure[J]. N Engl J Med, 2021, 384(2): 117-128. doi: 10.1056/NEJMoa2030183
[35] Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial[J]. Nat Med, 2022, 28(3): 568-574. doi: 10.1038/s41591-021-01659-1
[36] McDonagh TA, Metra M, Adamo M, Gardner RS, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
[37] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e876-e894.
[38] Tomasoni D, Fonarow GC, Adamo M, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction[J]. Eur J Heart Fail, 2022, 24(3): 431-441.
[39] McMurray J, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine[J]. Circulation, 2021, 143(9): 875-877.
[40] Giaccari A, Pontremoli R, Perrone Filardi P. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice[J]. Int J Cardiol, 2022, 351: 66-70.
[41] Kosiborod MN, Angermann CE, Collins SP, et al. Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure-Results From the EMPULSE Trial[J]. Circulation, 2022.
[42] Xie Y, Bowe B, Gibson AK, et al. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes[J]. J Am Heart Assoc, 2021, 10(11): e020237.
[43] Writing Committee, Maddox TM, Januzzi JL Jr, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2021, 77(6): 772-810.
[44] Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors[J]. Diabetes Obes Metab, 2019, 21(2): 434-438.
[45] Alkabbani W, Zongo A, Minhas-Sandhu JK, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study[J]. Can J Diabetes, 2021.
[46] Garla VV, Butler J, Lien LF. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives[J]. Curr Cardiol Rep, 2021, 23(6): 59.
[47] Peters AL, Buschur EO, Buse JB, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition[J]. Diabetes Care, 2015, 38(9): 1687-1693.
[48] Handelsman Y, Henry RR, Bloomgarden ZT, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6): 753-762.
[49] Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program[J]. Diabetologia, 2019, 62(6): 926-938.
[50] Scheen AJ. An update on the safety of SGLT2 inhibitors[J]. Expert Opin Drug Saf, 2019, 18(4): 295-311.
[51] Garla VV, Butler J, Lien LF. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives[J]. Curr Cardiol Rep, 2021, 23(6): 59.
-
图(1)
表(2)
计量
- 文章访问数: 6040
- PDF下载数: 12169
- 施引文献: 0